SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Altimmune Announces Dosing of First Patient In Phase 1b Clinical Trial Of NasoShield, A Single Dose Intranasal Anthrax Vaccine Candidate

Benzinga · -